Alto Neuroscience clinical trials we track

Check company identity source

Phase 2 10 trials

TrialDrugs studiedStatusPrimary completion
ALTO-207 in Adults With Treatment-resistant Depression (TRD)NCT07553637ALTO-207Recruiting2027-11Estimated
ALTO-100 in Bipolar Disorder With Depression (BD-D)NCT06656416ALTO-100Recruiting2027-09Estimated
Study of ALTO-300 in MDDNCT05922878ALTO-300Recruiting2026-12Estimated
Study of ALTO-101 in Patients With SchizophreniaNCT06502964ALTO-101, ALTO-101 Transdermal Delivery SystemRecruiting2026-02Estimated
PD, PK, and Safety of ALTO-203 in Patients With MDDNCT06391593ALTO-203 25 μg, ALTO-203 75 μgCompleted2025-04-14Actual
Phase 2b Study of ALTO-100 in MDDNCT05712187ALTO-100Completed2024-09-05Actual
ALTO-300 in DepressionNCT05118750ALTO-300 oral (PO) tabletCompleted2023-05-05Actual
ALTO-300 in Depression (ALTO-300-004)NCT05157945ALTO-300 PO TabletCompleted2023-04-26Actual
Pilot Decentralized TrialNCT05419869ALTO-100 PO TabletCompleted2023-01-13Actual
ALTO-100 in MDD and/or PTSDNCT05117632ALTO-100 PO tabletCompleted2022-12-01Actual

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
Study of ALTO-300 in MDD

NCT05922878 · Alto Neuroscience

· 1 field changed

Planned enrollment increased by 4 participants

Before: 321 participants (planned). After: 325 participants (planned).

Check registry source